Phaseline

Companies › Jubilant Therapeutics

Jubilant Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 1, 1 Phase 2; Oncology; next expected readout Jun 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
JBI-802
CoREST inhibitor dual targeting LSD1 and HDAC6
LSD1, HDAC (class I/II)Phase 1Essential Thrombocythemia (ET); Lung Cancer (NSCLC)Jun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07207395JBI-802Phase 2Lung Cancer (NSCLC)OncologyOct 2027
NCT07612280JBI-802Phase 1Essential Thrombocythemia (ET)OncologyJun 2028

Targets

LSD1 (1) HDAC (class I/II) (1)

Companies with the same targets

Xynomic Pharmaceuticals Unravel Biosciences Great Novel Therapeutics Biotech & Medicals Italfarmaco Daiichi Sankyo Chengdu Zenitar Biomedical Technology Acrotech Biopharma Novelwise Pharmaceutical Chipscreen Biosciences Novartis

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.